BioPharma Resources

Drug Trial Radar · NCT04035005

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,013 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,013

Actual

Start

Aug 12, 2019

Primary completion

Jan 15, 2025

Study completion Apr 15, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of ocrelizumab (Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study will consist of the following phases: screening, double-blind treatment, an optional post-double-progression ocrelizumab (PDP OCR) treatment, follow-up 1 (FU1), an optional open-label extension (OLE), and follow-up 2 (FU2).

Conditions

  • Multiple Sclerosis, Primary Progressive

Interventions

  • OcrelizumabDrug

    The first dose of ocrelizumab will be administered as two 300 milligrams (mg), IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending on if the previous dose was administered in one or two infusion, should be maintained between each infusion.

  • PlaceboDrug

    The first dose of placebo will be administered as two IV infusions given 14 days apart. For the subsequent doses, placebo will be administered as a single infusion every 24 weeks, with a minimum interval of 20 or 22 weeks, depending on if the previous dose was administered in one or two infusions, maintained between each infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12) in FASTime frame: Up to approximately 243 weeks
  2. Time to Onset of cCDP12 in Magnetic Resonance Imaging (MRI) Activity Analysis SetTime frame: Up to approximately 243 weeks

Locations

153 sites in 23 countries. Site status is shown where the registry gives one.

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • MS and Neuromuscular Center of Excellence

    Clearwater, Florida

  • Neurological Services of Orlando

    Orlando, Florida

  • Vero Radiology Associates

    Vero Beach, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company

    Columbus, Ohio

  • Columbus Neuroscience

    Westerville, Ohio

  • Albert Einstein Medical Center

    Philadelphia, Pennsylvania

  • Brain and Mind Research Institute

    Camperdown, New South Wales, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • MS & Neurologisch Revalidatie Centrum

    Overpelt, Belgium

  • UZ Antwerpen

    Edegem, Antwerpen, Belgium

  • Military Medical Academy HBAT

    Pleven, Bulgaria

  • Multiprofile Hospital For Active Treatment Avis Medica

    Pleven, Bulgaria

  • Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv. Naum EAD

    Sofia, Bulgaria

  • University of Alberta

    Edmonton, Alberta, Canada

  • Dalhousie Multiple Sclerosis Research Unit

    Halifax, Nova Scotia, Canada

  • BARLO MS Centre at St. Michael?s Hospital

    Toronto, Ontario, Canada

  • Recherche Sepmus Inc.

    Greenfield Park, Quebec, Canada

  • Clinica Colsanitas S.A. sede Clinica Universitaria Colombia

    Bogotá, Colombia

  • ?Hospital Neurologico de Colombia Fundacion Ivan Jimenez - El Neurologico?

    Medellín, Antioquia, Colombia

  • General Hospital Varazdin

    Varaždin, Croatia

  • Clinical Hospital Sestre Milosrdnice

    Zagreb, Croatia

  • University Hospital Center Zagreb

    Zagreb, Croatia

  • CHU de Bordeaux - Hôpital Pellegrin

    Bordeaux, France

  • Centre Hospitalier Universitaire de Clermont Ferrand

    Clermont-Ferrand, France

  • CHRU Nancy

    Nancy, France

  • Hopital Guillaume Et Rene Laennec

    Nantes, France

  • CHU de Nimes - Hopital Universitaire Caremeau

    Nîmes, France

  • CHU de Strasbourg - Hôpital de Hautepierre

    Strasbourg, Alsace, France

  • Pineo Medical Ecosystem LTD

    Tbilisi, Georgia

  • The First University Clinic of Tbilisi State Medical University

    Tbilisi, Georgia

  • Khechinashvili University Hospital

    Tbilisi, Georgia

  • AOU dell Universita degli Studi della Campania Luigi Vanvitelli Piazza Luigi Miraglia 2

    Naples, Campania, Italy

  • Azienda Ospedaliera Sant'andrea

    Rome, Lazio, Italy

  • IRCCS AOM Azienda Ospedaliera Metropolitana

    Genoa, Liguria, Italy

  • Ospedale San Raffaele S.r.l. - PPDS

    Milan, Lombardy, Italy

  • Fondazione Istituto Neurologico Mondino IRCCS

    Pavia, Lombardy, Italy

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.